UA130036C2 - Спосіб лікування стійкого до інгібітору cdk4/6 раку - Google Patents
Спосіб лікування стійкого до інгібітору cdk4/6 ракуInfo
- Publication number
- UA130036C2 UA130036C2 UAA202103017A UAA202103017A UA130036C2 UA 130036 C2 UA130036 C2 UA 130036C2 UA A202103017 A UAA202103017 A UA A202103017A UA A202103017 A UAA202103017 A UA A202103017A UA 130036 C2 UA130036 C2 UA 130036C2
- Authority
- UA
- Ukraine
- Prior art keywords
- elacestrant
- estrogen receptor
- cancer
- subject
- receptor alpha
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776323P | 2018-12-06 | 2018-12-06 | |
| PCT/US2019/065005 WO2020118213A1 (en) | 2018-12-06 | 2019-12-06 | Methods for treating cancer resistant to cdk4/6 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA130036C2 true UA130036C2 (uk) | 2025-10-22 |
Family
ID=69063871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA202103017A UA130036C2 (uk) | 2018-12-06 | 2019-12-06 | Спосіб лікування стійкого до інгібітору cdk4/6 раку |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20210330612A1 (https=) |
| EP (1) | EP3890834A1 (https=) |
| JP (1) | JP7504097B2 (https=) |
| KR (1) | KR20210100137A (https=) |
| CN (2) | CN113164779A (https=) |
| AU (1) | AU2019395093B2 (https=) |
| BR (1) | BR112021010110A2 (https=) |
| CA (1) | CA3121930A1 (https=) |
| EA (1) | EA202191283A1 (https=) |
| IL (1) | IL283659A (https=) |
| JO (1) | JOP20210137B1 (https=) |
| MA (1) | MA54388A (https=) |
| MX (1) | MX2021006411A (https=) |
| PH (1) | PH12021551319A1 (https=) |
| SG (1) | SG11202105531XA (https=) |
| UA (1) | UA130036C2 (https=) |
| WO (1) | WO2020118213A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102674902B1 (ko) | 2016-12-01 | 2024-06-14 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체 |
| IL320609A (en) | 2019-08-26 | 2025-07-01 | Arvinas Operations Inc | Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents |
| CN116744925A (zh) * | 2020-12-14 | 2023-09-12 | 阿尔维纳斯运营股份有限公司 | 用四氢萘衍生物作为雌激素受体降解剂治疗乳腺癌的方法 |
| GB202116745D0 (en) * | 2021-11-19 | 2022-01-05 | Institute Of Cancer Res Royal Cancer Hospital | Prognostic and treatment response predictive method |
| CN115369089A (zh) * | 2022-08-11 | 2022-11-22 | 中山大学孙逸仙纪念医院 | 两种er阳性her-2阴性乳腺癌cdk4/6抑制剂耐药株及其构建方法和用途 |
| CN116327894A (zh) * | 2023-04-10 | 2023-06-27 | 上海市第一妇婴保健院 | 一种治疗kras突变的卵巢癌的组合药物及其应用 |
| WO2025202871A1 (en) * | 2024-03-27 | 2025-10-02 | Pfizer Inc. | Methods for identifying biomarkers of treatment response and use thereof with a cdk4 inhibitor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9421264B2 (en) * | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| JP7019422B2 (ja) * | 2015-04-29 | 2022-02-15 | ラジウス ファーマシューティカルズ，インコーポレイテッド | 癌を治療するための方法 |
| KR102707399B1 (ko) * | 2017-01-05 | 2024-09-13 | 래디어스 파마슈티컬스, 인코포레이티드 | Rad1901-2hcl의 다형 형태 |
| IL279853B2 (en) * | 2018-07-04 | 2025-01-01 | Radius Pharmaceuticals Inc | Polymorphic forms of RAD 1901-2HCL |
-
2019
- 2019-12-06 CN CN201980081052.7A patent/CN113164779A/zh active Pending
- 2019-12-06 MX MX2021006411A patent/MX2021006411A/es unknown
- 2019-12-06 EP EP19829727.7A patent/EP3890834A1/en active Pending
- 2019-12-06 SG SG11202105531XA patent/SG11202105531XA/en unknown
- 2019-12-06 BR BR112021010110-1A patent/BR112021010110A2/pt unknown
- 2019-12-06 KR KR1020217020435A patent/KR20210100137A/ko not_active Ceased
- 2019-12-06 CN CN202411710355.XA patent/CN119548484A/zh active Pending
- 2019-12-06 AU AU2019395093A patent/AU2019395093B2/en active Active
- 2019-12-06 JP JP2021531818A patent/JP7504097B2/ja active Active
- 2019-12-06 MA MA054388A patent/MA54388A/fr unknown
- 2019-12-06 US US17/299,948 patent/US20210330612A1/en not_active Abandoned
- 2019-12-06 UA UAA202103017A patent/UA130036C2/uk unknown
- 2019-12-06 EA EA202191283A patent/EA202191283A1/ru unknown
- 2019-12-06 WO PCT/US2019/065005 patent/WO2020118213A1/en not_active Ceased
- 2019-12-06 CA CA3121930A patent/CA3121930A1/en active Pending
- 2019-12-06 PH PH1/2021/551319A patent/PH12021551319A1/en unknown
-
2021
- 2021-06-02 IL IL283659A patent/IL283659A/en unknown
- 2021-06-06 JO JOJO/P/2021/0137A patent/JOP20210137B1/ar active
-
2025
- 2025-06-26 US US19/250,779 patent/US20250319044A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN113164779A (zh) | 2021-07-23 |
| PH12021551319A1 (en) | 2022-05-16 |
| EP3890834A1 (en) | 2021-10-13 |
| AU2019395093A1 (en) | 2021-06-24 |
| KR20210100137A (ko) | 2021-08-13 |
| US20250319044A1 (en) | 2025-10-16 |
| JOP20210137A1 (ar) | 2023-01-30 |
| AU2019395093B2 (en) | 2025-01-23 |
| MX2021006411A (es) | 2021-07-21 |
| CA3121930A1 (en) | 2020-06-11 |
| US20210330612A1 (en) | 2021-10-28 |
| JOP20210137B1 (ar) | 2025-10-01 |
| BR112021010110A2 (pt) | 2021-08-24 |
| JP7504097B2 (ja) | 2024-06-21 |
| SG11202105531XA (en) | 2021-06-29 |
| JP2022511498A (ja) | 2022-01-31 |
| CN119548484A (zh) | 2025-03-04 |
| WO2020118213A1 (en) | 2020-06-11 |
| IL283659A (en) | 2021-07-29 |
| EA202191283A1 (ru) | 2021-10-13 |
| MA54388A (fr) | 2021-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA130036C2 (uk) | Спосіб лікування стійкого до інгібітору cdk4/6 раку | |
| US12582617B2 (en) | Methods for treating cancer | |
| Ciruelos et al. | Palbociclib and trastuzumab in HER2-positive advanced breast cancer: results from the phase II SOLTI-1303 PATRICIA trial | |
| KR102446839B1 (ko) | B-Raf 억제제와 제2 억제제를 포함하는 조합 요법 | |
| KR102035361B1 (ko) | 암의 병용 치료 | |
| Metzger Filho et al. | Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases | |
| JP2022520079A (ja) | Ｔｎｏ１５５及びｋｒａｓｇ１２ｃ阻害剤を含む医薬組合せ | |
| JP2022519375A (ja) | Ｔｎｏ１５５及びリボシクリブを含む医薬組合せ | |
| TW201943428A (zh) | 預防或治療腫瘤療法副作用的方法 | |
| JP2021527111A (ja) | Ｓ−エクオールを用いた乳癌の治療及び予防方法 | |
| KR20220067657A (ko) | 면역치료요법의 효능, 예후, 또는 내성 예측을 위한 바이오마커, 및 면역치료요법의 효능 증진을 위한 표적으로서 tctp의 용도 | |
| JP2020169222A (ja) | 癌を治療するための方法 | |
| US20230118053A1 (en) | Combination of anti-her2 antibody and cdk inhibitior for tumor treatment | |
| TW201806592A (zh) | 治療癌症的方法 | |
| US20250295656A1 (en) | Combination of lurbinectedin and immune checkpoint inhibitors | |
| JPWO2021021882A5 (https=) | ||
| Trédaniel et al. | Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small-cell lung cancer | |
| AU2025204567C1 (en) | Combination Of Lurbinectedin And Immune Checkpoint Inhibitor | |
| US20250241875A1 (en) | Methods for treating cancer in models harboring esr1 mutations | |
| KR101734652B1 (ko) | 독소루비신 내성 관련 유전자 및 이의 용도 | |
| Lang et al. | P06. 10. A THE MIRNA 216B-5P ACTS AS A PROMISING TUMOR-SUPPRESSOR BY MANIPULATING CELL CYCLE PROGRESSION IN HIGH-GRADE GLIOMA CELLS | |
| EA047283B1 (ru) | Способы лечения устойчивого к ингибиторам cdk4/6 рака | |
| Hoang | Improving traditional therapies for glioblastoma via cell cycle checkpoint kinase inhibition | |
| KR20070018108A (ko) | 시스플라틴 및 ｅｇｆｒ-억제제를 이용한 치료 |